Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

Mei Zeng1,2, Nicholas P Kwiatkowski1,2, Tinghu Zhang1,2, Behnam Nabet1,2, Mousheng Xu1,3, Yanke Liang1,2, Chunshan Quan1,2, Jinhua Wang1,2, Mingfeng Hao1,2, Sangeetha Palakurthi4, Shan Zhou4, Qing Zeng4, Paul T Kirschmeier1, Khyati Meghani5, Alan L Leggett1,2, Jun Qi1,3, Geoffrey I Shapiro4, Joyce F Liu7, Ursula A Matulonis7, Charles Y Lin8,9*, Panagiotis A Konstantinopoulos7*, Nathanael S Gray1,2*

1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States; 2Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States; 3Department of Medicine, Harvard Medical School, Boston, United States; 4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States; 5Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States; 6Early Drug Development Center, Dana-Farber Cancer Institute, Boston, United States; 7Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States; 8Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States; 9Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, United States

Abstract

High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors. We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy. However, targeting MYC directly has proven difficult. We screen small molecules targeting transcriptional and epigenetic regulation, and find that THZ1 - a chemical inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC. Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but requires the combined inhibition of CDK7, CDK12, and CDK13. In 11 patient-derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression. Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.

Introduction

Epithelial ovarian cancer (OC) is the fifth most common cause of female cancer death in the United States and the most lethal gynecologic malignancy (Siegel et al., 2017). High-grade serous ovarian carcinoma (HGSOC) represents the most common and aggressive histologic subtype of OC, and accounts for the majority of its deaths (Konstantinopoulos and Awtrey, 2012). Large-scale genomic studies have demonstrated that HGSOCs are characterized by high degree of genomic instability with high frequency of DNA copy number alterations and almost universal presence of TP53
mutations (Cancer Genome Atlas Research Network, 2011). Approximately 50% of HGSOCs exhibit an underlying defect in DNA repair via homologous recombination (HR) and are highly sensitive to double-strand-break-inducing agents such as platinum analogues and PARP-inhibitors (PARPi) (Konstantinopoulos et al., 2015). However, although first-line platinum-based chemotherapy results in clinically complete remissions in approximately 70% of OC patients, relapse occurs in more than 90% of these patients, at which point the disease is much less responsive to subsequent treatment and is essentially non-curable. Similarly, despite initial responses to PARPi among HR-deficient HGSOCs, acquired resistance occurs commonly and represents a significant barrier to the long-term survival of these patients (Lord and Ashworth, 2017). Overall, the outlook for patients with platinum and PARPi-resistant disease is poor, so novel therapeutic strategies are urgently needed (Vaughan et al., 2011).

The control of gene transcription involves a set of cyclin-dependent kinases (CDKs), including CDK7, CDK8, CDK9, CDK11, CDK12, CDK13, and CDK19, that play essential roles in transcription initiation and elongation by phosphorylating RNA polymerase II (RNAPII) and other components of the transcription apparatus (Larochelle et al., 2007; Zhou et al., 2012). Recent studies have shown that certain oncogenes, for example MYC, MYCN, and RUNX1 exhibit significant dependence on continuous active transcription, and that inhibition of the general transcriptional machinery may allow for highly selective effects on these oncogenes in cancer cells before global downregulation of transcription occurs (Kwiatkowski et al., 2014; Cao and Shilatifard, 2014; Chipumuro et al., 2014). The continuous active transcription of these oncogenes in cancer cells is often driven by exceptionally large clustered enhancer regions, termed super-enhancers, which are densely occupied by transcription factors and co-factors (Hnisz et al., 2013; Lovén et al., 2013). In this vein, it was recently shown that CDK7 mediates transcriptional addiction to a vital cluster of genes associated with super-enhancers in triple-negative breast cancer (TNBC), and that TNBC cells are exceptionally dependent on CDK7 (Wang et al., 2015). The CDK7 covalent inhibitor THZ1, which also inhibits the closely related kinases CDK12 and CDK13 (CDK12/13), has been also shown to directly suppress super-enhancer-associated oncogenic transcription in T-cell acute lymphoblastic leukemia, neuroblastoma and small cell lung cancer (Kwiatkowski et al., 2014; Chipumuro et al., 2014; Christensen et al., 2014).

Here, we identified THZ1 as a highly potent compound that downregulates MYC expression. THZ1 demonstrates exceptional in vivo activity in patient-derived xenograft (PDX) models of ovarian cancer that were platinum and PARPi resistant. Notably, suppression of MYC was only achieved by simultaneous inhibition of CDK7, CDK12, and CDK13. Our data suggest that combined inhibition of transcriptional CDKs with THZ1, or its derivatives, may be an effective approach for treating MYC-dependent ovarian cancer.

Results and discussion

MYC is frequently amplified in ovarian cancer and is essential for cancer cell growth

Previous large-scale studies of HGSOC demonstrated extensive copy number alterations (Cancer Genome Atlas Research Network, 2011). Among the total eight recurrent chromosome-arm gains, chromosome 8q has the most significant gains and occurred in 65% of the tumors (n = 489) (Cancer Genome Atlas Research Network, 2011). Analyzing the updated TCGA dataset that includes more patient samples also indicate the widespread 8q gain, in addition to 8 p loss (Figure 1A).

Inspired by earlier investigations of ovarian cancer reporting the amplification of 8q regions as well as that of MYC oncogene in 8q24 (Baker et al., 1990; Etemadmoghadam et al., 2009; Staebler et al., 2006), we focus on the amplification of MYC in ovarian cancer. Notably, ovarian cancer demonstrates the highest frequency of MYC amplification (Figure 1B), compared to many other tumor types. We further analyzed and found a significant correlation between the gene copy number of MYC and its gene expression level (assayed by RNA sequencing) (Figure 1C). Therefore, MYC has widespread amplification in ovarian cancer, and its amplification typically correlates with high-level expression of the MYC oncogene.
Figure 1. MYC is frequently amplified in ovarian cancer and required for cancer cell growth. (A) Copy number plots of TCGA high-grade serous ovarian cancer samples for chromosome 8 (top) and part of the q24 arm (bottom). Red color indicates a high chromosomal copy number ratio, blue represents low (see color key on the right). Data were analyzed and plotted using UCSC Xena Functional Genomics Browser (xena.ucsc.edu). (B) Frequency of MYC amplification across cancer types. (C) Correlation between MYC copy number and its gene expression in ovarian cancer. The relative copy number value and normalized RNA-seq expression values of MYC were downloaded from cBioportal and plotted in GraphPad Prism. Pearson correlation coefficient was measured. Figure 1 continued on next page.
Driven by the extensive alterations on both MYC gene copy and expression scales, we next proceeded to evaluate the functional role of MYC in OC lines. We utilized CRISPR/Cas9-mediated gene editing technique to disrupt the expression of MYC (Sanjana et al., 2014), and observed an efficient loss of MYC protein in cells infected with lentivirus encoding two independent MYC-targeting guide RNAs (Figure 1D, top). MYC-depleted KURAMOCHI and OVCAR8 cells showed a significant deficit in cell viability compared to control cells as determined by clonogenic growth survival assay (Figure 1D, bottom). In addition, we analyzed the large-scale CRISPR screen performed by Broad Institute, a study where they developed the CERES computational model to reduce the false-positive differential dependencies caused by multiple DNA breaks resulted from targeting amplified regions (Meyers et al., 2017). In the analysis illustrating MYC dependency in a total of 484 cancer cell lines, there is no statistical correlation between MYC dependency values and with MYC copy number (Figure 1—figure supplement 1A), indicating the successful computational elimination of effects introduced by targeting amplified MYC. Notably, ovarian cancer cells overall demonstrate a high dependence on MYC (indicated by the low CERES values), and as expected, MYC dependency is highly correlated with cell dependency on MAX – a partner of MYC for transcriptional regulation (Figure 1—figure supplement 1B). These data further confirm the functional roles of MYC for ovarian cancer cell proliferation and indicate MYC as a promising therapeutic target for ovarian cancer.

**Screening transcriptional/epigenetic regulators identifies THZ1 as a potent inhibitor for MYC expression in ovarian cancer cells**

Given the prominent gene amplification/overexpression of MYC and its critical roles for ovarian cancer cell growth, we next explored pharmacologic strategies for targeting MYC. Since the MYC protein lacks characteristics enabling specific and direct binding to small molecule compounds, recent studies have focused on approaches to interrupt the genesis of MYC transcript/protein or key downstream functions of MYC. In this regard, several studies have shown that inhibition of BET bromodomain proteins can effectively downregulate MYC transcription and consequently the growth of MYC-dependent cancer cells (Delmore et al., 2011; Mertz et al., 2011). Consistent with previous studies (Delmore et al., 2011), we found that MYC expression in the multiple myeloma line MM1.S is highly sensitive to JQ1; treating cells with JQ1 at nanomolar concentrations was sufficient to downregulate MYC protein abundance (Figure 1E, bottom). Surprisingly, this effect was not observed in ovarian cancer cells (Figure 1E, top), a phenotype reminiscent of that seen in other non-hematologic cancer cells, such as lung adenocarcinoma cells (Lockwood et al., 2012), and some triple-negative breast cancer cells (Shu et al., 2016).

To identify regulatory pathways that control MYC gene transcription in ovarian cancer, we proceeded to screen a selected group of chemicals. We selected 42 compounds, derived from the HMS small molecule library (http://lincs.hms.harvard.edu/db/sm/), targeting various transcriptional and/or epigenetic components, such as histone modification enzymes, transcriptional CDKs, transcriptional co-activators, and DNA modification enzymes (Figure 2A; Supplementary file 1). The compounds were used for treating two OC cell lines, KURAMOCHI and COV362. Whole cell lysates were then harvested for fluorescent immunoblotting, and MYC protein signal was normalized to that of loading control in the same membrane (Figure 2A; Figure 2—figure supplement 1). In both cell lines, these inhibitors display various effects on MYC protein abundance, and the most potent inhibitor is THZ1,
Figure 2. Targeted screen of transcriptional and epigenetic regulators identifies THZ1 as key transcriptional regulator of MYC. (A) Schematic diagram of a screen for small molecules that inhibit MYC expression. Ovarian cancer cells were treated with selected epigenetic/transcriptional inhibitors for 6 hr at a final concentration of 1 μM. Whole cell lysates were subjected to fluorescent immunoblotting with anti-MYC and anti-α-tubulin loading.
THZ1 represses MYC target genes in ovarian cancer cells

We next performed global gene expression profiling in ovarian cancer cells to investigate the effects of THZ1 on transcriptional programs. In two THZ1-sensitive cell lines KURAMOCHI (Ku) and COV362 (Cov), we treated cells for 6 hr with vehicle control or THZ1 at two concentrations (50 and 250 nM) in duplicates, and then subjected samples for RNA isolation, library construction, and sequencing.

We analyzed the actively expressed genes (n = 14,068) in two ovarian cancer cell lines and the global change of gene expression was displayed in a concentration-dependent manner upon THZ1 treatment, shown by the heatmaps (Figure 3A). A profound suppression of gene expression was observed following treatment of THZ1 at 250 nM in both cell lines, with 1060 genes downregulated
Figure 3. THZ1 represses MYC target genes in ovarian cancer cells. (A) Heatmaps showing row normalized gene expression for all actively expressed genes ($n = 14,068$) (cell count normalized FPKM > 1 in at least one sample). (B) Scatter plots comparing change in gene expression upon THZ1 treatment to gene expression levels in DMSO. X-axis shows the Log2 fold change of expression (THZ1/DMSO). Y-axis shows the adjusted log2 counts per million (CPM) expression in DMSO. Differentially regulated genes as determined by edgeR are shown for downregulated (blue) and upregulated.
(red) genes. A FDR adjusted p-value cutoff of 1e-3 and a log fold change (LFC) cutoff of 0.5 are used as the threshold for significance. (C) Left - Venn diagram showing the intersection of differential downregulated genes between Ku and Cov cells upon THZ1 250 nM treatment. Significance of overlap is determined by a fisher’s exact test. p-value and odds ratio are shown. Right - Scatter plots comparing the log2 fold change in gene expression upon THZ1 250 nM treatment between Ku and Cov cells. Differential downregulated genes that are shared between Ku and Cov are shown in blue. The pearson correlation of differential genes is shown (Rho = 0.76). (D) Bar plot showing gene sets from the MSigDB Hallmarks of Cancer that are significantly enriched (FDR q value < 1e-3) amongst the 685 genes shared as differentially downregulated between Ku and Cov upon 250 nM THZ1 treatment. MYC target gene sets are shown in red. Two MYC hallmark gene sets, MYC_targets_V1 and MYC_targets_V2 (shown in red), were also identified. (Figure 3—figure supplement 1). Next, we examined how many downregulated genes were shared between Ku and Cov cells and what the potential pathways these genes might be involved in. There were 685 differential downregulated genes been identified upon THZ1 250 nM treatment, shown by the Venn diagram (p-value for significance of overlap <2e-16) (Figure 3C, Left) and by the scatter plot(Figure 3C, Right), with the overlapped downregulated genes shown in blue (Pearson correlation coefficient Rho = 0.76). To search for the oncogenic pathways that were selectively downregulated by THZ1, we queried the Molecular Signature Database (MSigDB) Hallmarks of Cancer in Gene Set Enrichment Analysis (Broad Institute). G2M checkpoint and E2F Targets appeared to be the top two hallmark gene sets that were significantly enriched amongst the 685 genes in Ku and Cov upon THZ1 250 nM treatment. Two MYC hallmark gene sets, MYC_targets_V1 and MYC_targets_V2 (shown in red), were also identified (Figure 3D). Additionally, these two MYC hallmark gene sets were also significantly enriched when analyzed individually (Figure 3—figure supplement 2). When comparing the MYC target genes (defined from the HallMARKS_MYC_TARGETS_V2 gene set, in red) with all other active genes (in gray), they were significantly downregulated upon THZ1 250 nM treatment in both cell lines (Figure 3E). This analysis is consistent with THZ1 downregulating a MYC-dependent gene expression program.

**MYC and MCL-1 downregulation require the inhibition of both CDK7 and CDK12/13**

Given the polypharmacology of THZ1, we asked whether the loss of MYC and MCL-1 resulted from inhibition of CDK7, or CDK12/13, or combined inhibition of CDK7 and CDK12/13. To do this, we turned to two recently described compounds that were selective for CDK7 (YKL-1–116, Kalan et al., 2017) or CDK12/13 (THZ531, Zhang et al., 2016) (Figure 4A). Compared with THZ1 (Figure 2C), YKL-1–116 exhibited similar but less potent effects on MYC downregulation in two OC cell lines (Figure 4B–C, Figure 4—figure supplement 1A–B). Different from THZ1 and YKL-1–116, the CDK12/13 inhibitor, THZ531, has a unique effect on MYC expression: at low doses of THZ531 MYC expression is induced, while higher doses of THZ531 cause MYC to be repressed (Figure 4B–C, Figure 4—figure supplement 1A–B). To test whether the combined CDK7 and CDK12/13 inhibition enhances MYC and MCL-1 downregulation, we treated cells with the combination of YKL-1–116 and THZ531.Interestingly, we found that the combination of YKL-1–116 and THZ531 led to pronounced reduction of MYC and MCL-1, recapitulating the effects of THZ1 (Figure 4D–E, Figure 4—figure...
Figure 4. Downregulation of MYC and MCL-1 requires co-inhibition of CDK7 and CDK12/13 in KURAMOCHI cells. (A) Chemical structures of inhibitors and their primary protein targets. (B) KURAMOCHI cells were treated with increasing concentrations of YKL-1–116 or THZ531, with cell lysates prepared following 6 hr of treatment. (C) qPCR analysis of MYC and MCL-1 in YKL-1–116 or THZ531-treated KURAMOCHI cells for 6 hr. Student’s t-test was performed and data were presented as mean values ± SD of technical triplicates. (D) qPCR analysis of MYC and MCL-1 in single or combination
treatment with YKL-1–116 and THZ531 for 6 hr. Red arrows indicate an enhanced repression by the combination treatment. Student’s t-test was performed and data were presented as mean values ± SD of technical triplicates. (E) Combining YKL-1–116 and THZ531 efficiently downregulates MYC expression. KURAMOCHI cells were treated with increasing concentrations of YKL-1–116 (0.5 or 1 μM), in combination with increasing concentrations of THZ531 (0.0625, 0.125, 0.25, or 0.5 μM) for 6 hr before lysates were prepared for immunoblotting. Also see Figure 4—figure supplement 1, Figure 4—figure supplement 2.

DOI: https://doi.org/10.7554/eLife.39030.010

The following figure supplements are available for figure 4:

Figure supplement 1. Downregulation of MYC and MCL-1 requires co-inhibition of CDK7 and CDK12/13 in COV362 cells.
DOI: https://doi.org/10.7554/eLife.39030.011

Figure supplement 2. The mutant CDK7 (C312S) rescued THZ1-induced MYC downregulation and cell growth inhibition by YKL-1–116.
DOI: https://doi.org/10.7554/eLife.39030.012

THZ1 suppresses the growth of patient-derived ovarian tumors

Next, we evaluated the therapeutic efficacy of THZ1 in ovarian tumor models. Although THZ1 targets expression of more genes than MYC via CDK7/12/13 inhibition, its high efficiency in downregulating MYC and other genes that are critical for ovarian cancer cells, such as MCL-1, provides strong rationale for translational development. We used the orthotopic ovarian patient-derived xenografts (PDX) models that we established previously (Liu et al., 2017). The primary tumor cells were transduced with luciferase gene to enable the use of bioluminescent imaging for measurement of tumor growth.

To compare the single agent potency of THZ1 with combination effect of drugs, we performed a combination study with THZ1 and PARP inhibitor Olaparib, a FDA-approved drug in relapsed ovarian cancer irrespective of BRCA1/2 status. We first conducted tolerability studies and found that THZ1 administered by intraperitoneal injection (IP) twice daily (BID) at 10 mg/kg was well-tolerated with no signs of overt toxicity as judged by body weight and animal behavior (data not shown). In efficacy studies, we first implanted ascites-derived ovarian tumor cells into the mice, and after 7 days
assigned animals into four groups receiving vehicle control (10 ml/kg, PO, QD) or THZ1 (10 mg/kg, IP, BID) or Olaparib (100 mg/kg, PO, QD) or combo (THZ1 + Olaparib) for 27 days, with bioluminescent imaging performed at 5 timepoints (0, 6, 13, 20, and 27 days) (Figure 5A–B). Consistent with previous studies of THZ1 or Olaparib, mouse body weight was minimally affected by the inhibitor (Figure 5—figure supplement 1). In all the 11 independent PDX models investigated, the administration of THZ1 caused significant inhibition on tumor cell growth (Figure 5B–C). Notably, in four models (DF-149, 172, 83, and 86), THZ1 induced complete inhibition on tumor growth (Figure 4C) in model (DF-181, termed category iii) did not demonstrate tumor regression and rather present slower tumor cell growth upon THZ1 treatment. The administration of Olaparib did not dramatically inhibit tumor growth, and only showed very modest effect in three models (DF-106, 68, and 83). The combination of THZ1 and Olaparib, however, displayed synergistic effect and further inhibition on tumor growth was observed in five models (DF-106, 118, 86, 181, and 68). In addition, we found that the protein abundance of both MYC and MCL-1 in the tumor was nearly abrogated following THZ1 treatment (Figure 5D). Overall, the potency of THZ1 in suppressing tumor growth in our ovarian tumor models is striking, given that tumor regression is rarely observed in previous studies using THZ1. The combination study indicated that combining THZ1 with clinical PARP inhibitors could be promising future therapeutic approach for treating ovarian cancer.

In summary, our study demonstrates an exceptional antitumor activity of THZ1 in models of ovarian cancer and point to at least part of its mechanistic actions whereby an oncogenic transcription factor with widespread alteration in ovarian cancer, MYC, is strongly suppressed by this compound. Thus the current study provides a compelling rationale for investigating THZ1, or its derivatives, for treating MYC-dependent ovarian cancer in the clinic. In addition, we find that suppression of MYC expression can only be achieved by simultaneous inhibition of CDK7, CDK12 and CDK13, further demonstrating the advantage of polypharmacology in overcoming functional redundancy in transcriptional regulation through targeting multiple CDKs.

### Materials and methods

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Antibody                         | Rabbit monoclonal anti-c-MYC (Y69) | ABCAM | Cat# ab32072; RRID: AB_731658 | 1:1000 dilution |
| Antibody                         | Rabbit polyclonal anti-MCL-1 | Santa Cruz Biotechnology | Cat# sc-819; RRID: AB_2144105 | 1:1000 dilution |
| Antibody                         | Mouse monoclonal anti-alpha-Tubulin | Cell Signaling Technology | Cat# 3873S; RRID: AB_1904178 | 1:5000 dilution |
| Antibody                         | Rabbit monoclonal anti-HA tag | Cell Signaling Technology | Cat# 3724; RRID: AB_1549585 | 1:1000 dilution |
| Antibody                         | Rabbit polyclonal anti-GAPDH | Cell Signaling Technology | Cat# 2118; RRID: AB_561053 | 1:3000 dilution |
| Antibody                         | Rabbit polyclonal anti-RNA Polymerase II RPB1 | Bethyl Laboratories | Cat# A300-653A; RRID: S19334 | 1:500 dilution |
| Antibody                         | Rat monoclonal anti-RNA Polymerase II subunit B1 (phosphor CTD ser-2) | EMD Millipore | Cat# 04–1571; RRID: AB_2687450 | 1:1000 dilution |
| Antibody                         | Rat monoclonal anti-RNA Polymerase II subunit B1 (phosphor CTD ser-5) | EMD Millipore | Cat# 04–1572; RRID: AB_2687451 | 1:5000 dilution |

Continued on next page
Figure 5. THZ1 abrogates the growth of patient-derived high-grade serous ovarian cancer cells in vivo. (A) A schematic diagram of the experimental design. (B) Luminescence picture of luciferized PDX mice (e.g. DF-106) at day 0 and day 27, treated with vehicle control (10 ml/kg, PO, QD) or THZ1 (10 mg/kg, IP, BID) or Olaparib (100 mg/kg, PO, QD) or Combo (THZ1 + Olaparib), Luminescence scale bar was shown on the right. (C) Luminescence Figure 5 continued on next page.
Figure 5 continued

signal of the tumor in 11 PDX models (n = 44 mice) treated with vehicle control or THZ1 or Olaparib or Combo. (D) Following the last treatment on day 27, tumor ascites from 5 PDX models (n = 10 mice) were harvested for the preparation of whole cell lysates followed by immunoblotting using the indicated antibodies. Also see Figure 5—
figure supplement 1.
DOI: https://doi.org/10.7554/eLife.39030.013

The following figure supplement is available for figure 5:

**Figure supplement 1.** Body weight measurement of the 11 PDX models (n = 44 mice) treated with vehicle control (10 ml/kg, PO, QD) or THZ1 (10 mg/kg, IP, BID) or Olaparib (100 mg/kg, PO, QD) or Combo.
DOI: https://doi.org/10.7554/eLife.39030.014

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Antibody                          | Rat monoclonal anti-RNA Polymerase II subunit B1 (phosphor CTD ser-7) | EMD Millipore | Cat# 04–1570; RRID: AB_2687452 | 1:5000 dilution |
| Peptide, recombinant protein      | THZ1        | Synthesized in our laboratory |             |                        |
| Peptide, recombinant protein      | THZ531      | Synthesized in our laboratory |             |                        |
| Peptide, recombinant protein      | YKL-1–116   | Synthesized in our laboratory |             |                        |
| Commercial assay or kit           | CellTiter-Glo Luminescent Cell Viability Assay | Promega | Cat# G7573 |                       |
| Commercial assay or kit           | RNeasy Plus Mini kit | Qiagen | Cat# 74136 |                       |
| Commercial assay or kit           | High-Capacity RNA-to-cDNA Kit | Applied Biosystems | Cat# 4387406 |                       |
| Commercial assay or kit           | SYBR Select Master Mix | Applied Biosystems | Cat# 4472908 |                       |
| Cell line (Homo sapiens)          | KURAMOCHI   | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL 1345 |                       |
| Cell line (Homo sapiens)          | COV362      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_2420 |                       |
| Cell line (Homo sapiens)          | OVCAR8      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_1629 |                       |
| Cell line (Homo sapiens)          | IGROV1      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_1304 |                       |
| Cell line (Homo sapiens)          | SKOV3       | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_0532 |                       |
| Cell line (Homo sapiens)          | CAOV3       | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_0201 |                       |
| Cell line (Homo sapiens)          | OVCAR3      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_0465 |                       |

Continued on next page
### Reagent type (species) or resource

| Reagent type (species) or resource | Designation | Source or reference | Identifiers | Additional information |
|-----------------------------------|-------------|---------------------|-------------|------------------------|
| Cell line (Homo sapiens)          | OVCAR4      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_1627 |
| Cell line (Homo sapiens)          | OVSAHO      | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_3114 |
| Cell line (Homo sapiens)          | PEO1        | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_Y032 |
| Cell line (Homo sapiens)          | JHOS2       | Panagiotis A. Konstantinopoulos’s laboratory | RRID:CVCL_4647 |
| Cell line (Homo sapiens)          | 293T        | Jean Zhao’s laboratory |            |
| Cell line (Homo sapiens)          | MM1.S       | James Bradner’s laboratory |            |
| Recombinant DNA reagent           | pLenti_crispr_sgGFP | This paper | Plasmid |
| Recombinant DNA reagent           | pLenti_crispr_sgMYC_1 | This paper | Plasmid |
| Recombinant DNA reagent           | pLenti_crispr_sgMYC_2 | This paper | Plasmid |
| Recombinant DNA reagent           | pLenti_crispr_sgMCL1_1 | This paper | Plasmid |
| Recombinant DNA reagent           | pLenti_crispr_sgMCL1_2 | This paper | Plasmid |
| Recombinant DNA reagent           | pTrex_HA_CDK7 WT | This paper | Plasmid |
| Recombinant DNA reagent           | pTrex_HA_CDK7 C312S | This paper | Plasmid |
| Software, algorithm               | GraphPad Prism | Graphpad Software Inc | https://www.graphpad.com/scientific-software/prism/ |
| Software, algorithm               | Image Studio Lite | LI-COR Biosciences | https://www.licor.com/bio/products/software/image_studio_lite/ |
| Software, algorithm               | ImageJ      | National Institutes of Health | https://imagej.nih.gov/ij/ |
| Software, algorithm               | Vector NTI  | Invitrogen | https://www.thermofisher.com/us/en/home/life-sciences/ cloning/vector-nti-software.html |

### Cell culture

All cells were grown in RPMI1640 or DMEM medium (Life Technologies), supplemented with 10% fetal bovine serum (Gibco), 50 units/mL penicillin, 50 units/mL streptomycin, and maintained in humidified 37°C/5%CO₂ incubator. Ovarian cancer cell lines, including KURAMOCHI, COV362, IGROV1, OVCAR8, OVSAHO, SKOV3, CAOV3, JHOS2, PEO1, OVCAR3 and OVCAR4, were generous gifts from Panos Konstantinopoulos’s laboratory at Dana-Farber Cancer Institute. All the cell lines have been tested to be mycoplasma-free using MycoAlert Mycoplasma Detection Kit (Lonza).
Immunoblotting
Cells were washed once with 1x phosphate buffered saline (PBS) and then lysed in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) supplemented with protease and phosphatase inhibitors (Roche). Protein concentrations were determined by using the Pierce BCA protein assay kit (Life Technologies). Equal amount of protein was resolved on SDS-PAGE and was subsequently transferred onto nitrocellulose membrane (Bio-Rad). The membrane was blocked with Odyssey block buffer TBS (LI-COR Biosciences) and was then incubated with primary antibodies in 20% of Odyssey block buffer TBST (with 0.1% Tween20) overnight at 4°C with gentle rotating. After washing, the membrane was incubated with fluorophore-conjugated secondary antibodies (1: 10,000) in 20% of Odyssey block buffer TBST (with 0.1% Tween20) for 1 hr at room temperature. The membrane was then washed three times in TBST and scanned with an Odyssey Infrared scanner (Li-Cor Biosciences). Primary antibodies include anti-alpha-Tubulin (Cell Signaling Technology # 3873S), anti-c-MYC (Y69) (ABCAM # ab32072), anti-MCL-1(S-19) (Santa Cruz # sc-819), anti-RNA polymerase II (Bethyl Laboratories #A300-653A), anti-RNA polymerase II subunit B1 (phospho CTD Ser-2, clone 3E10) (Millipore #04–1571), anti-RNA polymerase II subunit B1 (phospho-CTD Ser-5, clone 3E8) (Millipore #04–1572), anti-RNA polymerase II subunit B1 (phospho-CTD Ser-7, clone 4E12) (Millipore #04–1570), GAPDH (Cell Signaling Technology #2118), and anti-HA-tag (C29F4) (Cell Signaling Technology #3724). Secondary antibodies include IRDye 800CW Goat anti-Rabbit IgG (LICOR Biosciences #926–32211), IRDye 680LT Goat anti-Mouse IgG (LICOR Biosciences #926–68020), and IRDye 680RD Goat anti-Rat IgG (LICOR Biosciences #925–68076).

Plasmids and primers
Plasmids: pLenti_CRISPR_v2 vector was ordered from Addgene (Addgene #52961).
- pLenti_sgGFP, pLenti_sgMYC_1, pLenti_sgMCL1_1, pLenti_sgMCL1_2, pTrex_-HA_cdk7 WT, and pTrex_HA_cdk7 C312S lentiviral plasmids were made in our laboratory.
- Primers for cloning sgRNA into pLenti_CRISPR_v2 vector
  - sgGFP_1F: CACCGGGGCGAGGAGCTGTTCACCG
  - sgGFP_1R: AAACCGGTGAACAGCTCCTCGCCCC
  - sgMYC_1F: CACCGAACGTTGAGGGGCATCGTCG
  - sgMYC_1R: AAACCGACGATGCCCCTCAACGTTC
  - sgMYC_2F: CACCGGCCGTATTTCTACTGCGACG
  - sgMYC_2R: AAACCGTCGCAGTAGAAATACGGCC
  - sgMCL1_1F: CACCGGCTTCCGCCAATCACCGCGC
  - sgMCL1_1R: AAACGCGCGGTGATTGGCGGAAGCC
  - sgMCL1_2F: CACCGCTCGGCCCGGCGAGAGATAG
  - sgMCL1_2R: AAACCTATCTCTCGCCGGCGAGAC
- Primers for qPCR:
  - GAPDH_qPCR_forward: GGTCTCCTCTGACTTCAACA
  - GAPDH_qPCR_reverse: GTGAGGGTCTCTCTCTTCCT
  - MYC_qPCR_forward: GTAGAGGTCTCTCCTTCTCTTCT
  - MYC_qPCR_reverse: CTGCTGTGTGTGTACGTGT
  - MCL1_qPCR_forward: TGCTCGGAAAACTGACACATCA
  - MCL1_qPCR_reverse: TAGCCACAAGGCACCAAAAA

Virus infection
Lentiviruses were generated in HEK293T cells by transfecting cells with packaging DNA plus pLenti_-CRISPR plasmids. Typically, 2 µg pLenti_-CRISPR plasmid encoding sgRNA, 1.5 µg pCMVdrR8.91, and 0.5 µg pMD2-VSVG, 12 µl Lipofectamin2000 (Invitrogen) were used. DNA and lipid were pre-diluted in 300 µl Opti-MEM (Invitrogen) individually and then mixed well gently. After 30 min of incubation at RT, the DNA-lipid mixtures were added dropwise to HEK293T cells (2 × 10^6 cells were seeded in one T-25 flask, one day prior to transfection). Viral supernatant was collected 2 and 3 days after transfection, filtered through 0.45 µm membranes, and added to target cells in the presence of polybrene (8 µg/ml, Millipore). Target cells were infected twice with the virus at 48 hr and 72 hr later. Puromycin (1 µg/ml for KURAMOCHI and OVCAR8; 2 µg/ml for SKOV3) was used to treat cells for 2 days for selection, which eliminated all cells in an uninfected control group. Cells were
harvested 4 days after the initial viral infection and subjected them for either western blotting to assess the knockdown efficiency or for clonogenic cell growth assay. For lentiviral infection with pTrex_HA_cdk7 WT and pTrex_HA_cdk7 C312S plasmids, cells were infected as described above, and were selected with G418 (1 mg/ml) for 5 days then treated with 0.2 μg/ml Doxycycline for 1 day to induce the HA tagged-CDK7 overexpression. Doxycycline was replenished every 3 days during the following assays.

**Cell proliferation assays**
After virus infection and selection with puromycin, cells were seeded in 12-well plates (at the density of $5 \times 10^3$) in 1 ml medium. 14 days later, cells were fixed with 1% formaldehyde for 15 minutes, and stained with crystal violet (0.05%, wt/vol), a chromatin-binding cytochemical stain for 15 minutes. The plates were washed extensively in plenty of deionized water, dried upside-down on filter paper, and imaged with Epson scanner.

For the 3-day cell proliferation assay in 96-well plate, cells were plated at the density of 6000 to 10,000 cells per well and treated with THZ1 or YKL-1–116 of various concentrations on the next day. After 72 hr incubation, CellTiter-Glo reagent (Promega #G7572) was added to cells directly and luminescent signal was read on a plate reader (Perkin Elmer EnVision).

**RNA extraction**
Cells were plated in six-well plates and allowed to adhere overnight. Following treatment with compounds for 6 hr, cells were lysed, homogenized using QIAshredder spin column (Qiagen #79654), and subjected to total RNA extraction using RNeasy Plus Mini kit (Qiagen #74136). This kit contains gDNA columns to remove genomic DNA, according to the manufacturer’s instructions.

**RT-qPCR**
First strand cDNA was synthesized from 2 μg of total RNA using The High Capacity cDNA Reverse Transcription Kit (Life technologies #4368814). The cDNAs were diluted 15-fold in deionized water and then mixed with specific primers (10 μM) and 2X SYBR Select Master Mix (Applied Biosystems #4472908). The reactions were set up in MicroAmp Fast Optical 96-Well Reaction Plate (Life Technologies #4346906) and were run on 7500 Real-Time PCR System (Applied Biosystems). The GAPDH gene was used as a housekeeping gene control. Relative gene expression was calculated using the comparative method ($2^{-\Delta\Delta Ct}$).

**RNA-sequencing**
Following total RNA extraction, cell-count-normalized RNA samples were mixed with the RNA standards - External RNA Control Consortium (ERCC) Spike-In Mix (Ambion, 4456740) prior to library construction (Lovén et al., 2012). Libraries were prepared using TruSeq Stranded mRNA Library Prep Kit (Illumina), and equimolar libraries were multiplexed and sequenced on an Illumina NextSeq 500 (single end 75 bp reads) by the Molecular Biology Core Facility at the Dana-Farber Cancer Institute. Fastq files were aligned to human genome build hg19 using HiSat with default parameters. Transcripts were assembled, and Fragments Per Kilobase of transcript per Million mapped reads (FPKM) values were generated using cuffquant and cuffnorm from the cufflinks pipeline (Trapnell et al., 2010). FPKM values were then normalized to synthetic ERCC spike-in RNAs as described previously (Lovén et al., 2012). A transcript was considered to be expressed in each data set if in at least one experimental condition the normalized FPKM >1.

**Animal studies**
All animal experiments were conducted in accordance with the animal use guidelines from the NIH and with protocols (Protocol # 11–044) approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. We used the ovarian patient-derived xenografts (PDX) models that we established previously (Liu et al., 2017). The primary tumor cells were transduced with luciferase gene to enable the use of non-invasive bioluminescent imaging (BLI) for measurement of tumor growth. Briefly, ovarian cancer cells were taken from consented patients with HGSOC and implanted intraperitoneally into immunocompromised NOD-SCID IL2Rnull mice (NSG, Jackson Laboratory). $5 \times 10^6$ ascites-derived cells were implanted in each mouse and 7 days post implantation, mice were
imaged by BLI and assigned to four groups of treatment with vehicle control via oral gavage (PO) once daily (QD) at the dose of 10 ml/kg; THZ1 intraperitoneally (IP) twice daily (BID) at the dose of 10 mg/kg; Olaparib via PO, QD at the dose of 100 mg/kg; the combination of THZ1 and Olaparib. Tumor growth was assessed every 7 days (0, 6, 13, 20, 27 days) using BLI until day 27. Upon harvesting, tumors or other tissues were snap-frozen in liquid nitrogen for preparation of lysates and immunoblotting.

Data availability
RNA-sequencing data reported in this paper has been deposited to the NCBI GEO and are available under the accession number GSE116282.

Acknowledgements
We thank Dr. Yubao Wang at Dana-Farber Cancer Institute for fruitful discussions of the study and his critical reading of the manuscript. The study was supported by NIH R01 CA197336-02 (NSG), R01 CA179483-02 (NSG), Department of Defense W81XWH-14-OCR-P-OCACAOC140632 award (PAK), Cancer Prevention Research Institute of Texas RR150093 (CYL), NIH and NCI R01CA215452-01 (CYL), Pew-Stewart Scholar for Cancer Research (CYL), and American Cancer Society Postdoctoral Fellowship PF-17-010-01-CDD (BN).

Additional information
Competing interests
Nicholas P Kwiatkowski, Tinghu Zhang: is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals. Charles Y Lin: is a consultant of Jnana Therapeutics and is a shareholder and inventor of IP licensed to Syros Pharmaceuticals. Nathanael S Gray: is an inventor on a patent application covering THZ1 (patent application number WO/2014/063068 A1), which is licensed to Syros Pharmaceuticals. Is a scientific founder and equity holder of Syros Pharmaceuticals, C4 Therapeutics, Petra Pharma, Gatekeeper Pharmaceuticals, and Soltego. The other authors declare that no competing interests exist.

Funding

| Funder                                 | Grant reference number                        | Author                      |
|----------------------------------------|------------------------------------------------|-----------------------------|
| National Cancer Institute              | NIH R01 CA197336-02                            | Nathanael S Gray            |
| National Cancer Institute              | NIH R01 CA179483-02                            | Nathanael S Gray            |
| U.S. Department of Defense             | W81XWH-14-OCR-P-OCACAOC140632 award             | Panagiotis A Konstantinopoulos |
| Cancer Prevention and Research Institute of Texas | RR150093                                      | Charles Y Lin               |
| National Cancer Institute              | R01CA215452-01                                 | Charles Y Lin               |
| American Cancer Society                | Postdoctoral Fellowship PF-17-010-01-CDD       | Behnam Nabet                |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Mei Zeng, Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Writing—original draft, Writing—review and editing; Nicholas P Kwiatkowski, Conceptualization, Data curation, Supervision, Project administration, Writing—review and editing; Tinghu Zhang, Resources, Supervision, Project administration; Behnam Nabet, Data curation, Software, Methodology; Mousheng Xu, Data curation, Software, Formal analysis, Methodology; Yanke Liang, Chunshan Quan, Mingfeng Hao, Alan L Leggett, Investigation, Methodology; Jinhua Wang, Khyati Meghan, Resources, Investigation; Sangeetha Palakurthi, Data curation, Supervision, Investigation; Shan Zhou, Qing Zeng, Data curation, Investigation; Paul T Kirschmeier, Supervision, Investigation; Jun Qi,
Resources, Funding acquisition; Geoffrey I Shapiro, Joyce F Liu, Resources, Supervision; Ursula A Matulonis, Resources, Formal analysis, Funding acquisition; Charles Y Lin, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing—review and editing; Panagiotis A Konstantopoulos, Resources, Supervision, Writing—original draft, Project administration, Writing—review and editing; Nathanael S Gray, Conceptualization, Resources, Supervision, Funding acquisition, Project administration, Writing—review and editing

Author ORCIDs
Mei Zeng http://orcid.org/0000-0001-5316-3522
Behnam Nabet https://orcid.org/0000-0002-6738-4200
Charles Y Lin https://orcid.org/0000-0002-9155-090X
Nathanael S Gray http://orcid.org/0000-0001-5354-7403

Ethics
Animal experimentation: All animal experiments were conducted in accordance with the animal use guidelines from the NIH and with protocols (Protocol # 11-044) approved by the Dana-Farber Cancer Institute Animal Care and Use Committee. Full details are described in Materials and Methods - Animal Studies.

Decision letter and Author response
Decision letter https://doi.org/10.7554/eLife.39030.022
Author response https://doi.org/10.7554/eLife.39030.023

Additional files

Supplementary files
- Supplementary file 1. Table of epigenetic and transcriptional compound screen. DOI: https://doi.org/10.7554/eLife.39030.016
- Supplementary file 2. Table of normalized MYC expression values. DOI: https://doi.org/10.7554/eLife.39030.017
- Transparent reporting form DOI: https://doi.org/10.7554/eLife.39030.018

Data availability
RNA sequencing data have been deposited in GEO under accession code GSE116282.

The following dataset was generated:

| Author(s)               | Year | Dataset title                                      | Dataset URL                                           | Database and Identifier          |
|-------------------------|------|----------------------------------------------------|------------------------------------------------------|---------------------------------|
| Zeng M, Xu M, Charles Y Lin, Nathanael S Gray | 2018 | Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116282 | Gene Expression Omnibus, GSE116282 |

References

Akhtar MS, Heidemann M, Tietjen JR, Zhang DW, Chapman RD, Eick D, Ansari AZ. 2009. TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. *Molecular Cell* **34**:387–393. DOI: https://doi.org/10.1016/j.molcel.2009.04.016, PMID: 19450536

Baker VV, Borst MP, Dixon D, Hatch KD, Singleton HM, Miller D. 1990. c-myc amplification in ovarian cancer. *Gynecologic Oncology* **38**:340–342. DOI: https://doi.org/10.1016/0090-8258(90)90069-W, PMID: 22275455

Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. *Nature* **474**:609–615. DOI: https://doi.org/10.1038/nature10166, PMID: 21720365

Cao K, Shilatifard A. 2014. Inhibit globally, act locally: CDK7 inhibitors in cancer therapy. *Cancer Cell* **26**:158–159. DOI: https://doi.org/10.1016/j.ccr.2014.07.020, PMID: 25117707

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. 2012. The cBio cancer genomics portal: an open...
Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ. 2011. Targeting MYC dependence in cancer by inhibiting BET bromodomains. *PNAS* **108**:16669–16674. DOI: https://doi.org/10.1073/pnas.1108190108, PMID: 21949397

Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, Goodale A, Lee Y, Ali LD, Jiang G, Lubonja R, Harrington WF, Strickland M, Wu T, Hawes DC, Zhivich VA, et al. 2017. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. *Nature Genetics* **49**:1779–1784. DOI: https://doi.org/10.1038/ng.3984, PMID: 29083409

Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genome-wide libraries for CRISPR screening. *Nature Methods* **11**:783–784. DOI: https://doi.org/10.1038/nmeth.3047, PMID: 25075903

Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huj SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Brown J, D’Santos C, Krop IE, Dillon D, McKeown M, et al. 2016. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. *Nature* **529**:413–417. DOI: https://doi.org/10.1038/nature16508, PMID: 26735014

Siegel RL, Miller KD, Jemal A. 2017. Cancer statistics, 2017. *CA: A Cancer Journal for Clinicians* **67**:7–30. DOI: https://doi.org/10.3322/caac.21387, PMID: 28055103

Staebler A, Karberg B, Behm J, Kuhlmann P, Neubert U, Schmidt H, Korsching E, Bürger H, Lelle R, Kiesel L, Böcker W, Shih I, Buchweitz O. 2006. Chromosomal losses of regions on 8q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. *Genes, Chromosomes and Cancer* **45**:905–917. DOI: https://doi.org/10.1002/gcc.20356, PMID: 16845658

Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nature Biotechnology* **28**:511–515. DOI: https://doi.org/10.1038/nbt.1621, PMID: 20436464

Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, et al. 2011. Rethinking ovarian cancer: recommendations for improving outcomes. *Nature Reviews Cancer* **11**:719–725. DOI: https://doi.org/10.1038/nrc3144, PMID: 21941283

Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee Ti, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, Gray NS, Zhao JJ. 2015. CDK7-dependent transcriptional addiction in triple-negative breast cancer. *Cell* **163**:174–186. DOI: https://doi.org/10.1016/j.cell.2015.08.063, PMID: 26406377

Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS. 2016. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. *Nature Chemical Biology* **12**:876–884. DOI: https://doi.org/10.1038/nchembio.2166, PMID: 27571479

Zhou Q, Li T, Price DH. 2012. RNA polymerase II elongation control. *Annual Review of Biochemistry* **81**:119–143. DOI: https://doi.org/10.1146/annurev-biochem-052610-095910, PMID: 22404626